BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moustafa SR, Al-Rawi KF, Stoyanov D, Al-Dujaili AH, Supasitthumrong T, Al-Hakeim HK, Maes M. The Endogenous Opioid System in Schizophrenia and Treatment Resistant Schizophrenia: Increased Plasma Endomorphin 2, and κ and μ Opioid Receptors Are Associated with Interleukin-6. Diagnostics (Basel) 2020;10:E633. [PMID: 32858974 DOI: 10.3390/diagnostics10090633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Shnayder NA, Khasanova AK, Strelnik AI, Al-zamil M, Otmakhov AP, Neznanov NG, Shipulin GA, Petrova MM, Garganeeva NP, Nasyrova RF. Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia. IJMS 2022;23:11324. [DOI: 10.3390/ijms231911324] [Reference Citation Analysis]
2 Panov GP. Early Markers in Resistant Schizophrenia: Effect of the First Antipsychotic Drug. Diagnostics 2022;12:803. [DOI: 10.3390/diagnostics12040803] [Reference Citation Analysis]
3 Smesam HN, Qazmooz HA, Khayoon SQ, Almulla AF, Al-hakeim HK, Maes M. Pathway Phenotypes Underpinning Depression, Anxiety, and Chronic Fatigue Symptoms Due to Acute Rheumatoid Arthritis: A Precision Nomothetic Psychiatry Analysis. JPM 2022;12:476. [DOI: 10.3390/jpm12030476] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Bodnar RJ. Endogenous opiates and behavior: 2020. Peptides 2022. [DOI: 10.1016/j.peptides.2022.170752] [Reference Citation Analysis]
5 Mousa RF, Smesam HN, Qazmooz HA, Al-Hakeim HK, Maes M. A pathway phenotype linking metabolic, immune, oxidative, and opioid pathways with comorbid depression, atherosclerosis, and unstable angina. CNS Spectr 2021;:1-15. [PMID: 34039448 DOI: 10.1017/S1092852921000432] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Almulla AF, Al-Rawi KF, Maes M, Al-Hakeim HK. In schizophrenia, immune-inflammatory pathways are strongly associated with depressive and anxiety symptoms, which are part of a latent trait which comprises neurocognitive impairments and schizophrenia symptoms. J Affect Disord 2021;287:316-26. [PMID: 33812245 DOI: 10.1016/j.jad.2021.03.062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]